These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12071782)

  • 1. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART.
    Brown EG
    Drug Saf; 2002; 25(6):445-52. PubMed ID: 12071782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA).
    Brown EG
    Drug Saf; 2003; 26(3):145-58. PubMed ID: 12580645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.
    Bousquet C; Lagier G; Lillo-Le Louët A; Le Beller C; Venot A; Jaulent MC
    Drug Saf; 2005; 28(1):19-34. PubMed ID: 15649103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM).
    Yokotsuka M; Aoyama M; Kubota K
    Int J Med Inform; 2000 Jul; 57(2-3):139-53. PubMed ID: 10961570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using MedDRA: implications for risk management.
    Brown EG
    Drug Saf; 2004; 27(8):591-602. PubMed ID: 15154830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MedDRA and pharmacovigilance: a complex and little-evaluated tool.
    Prescrire Int; 2016 Oct; 25(175):247-250. PubMed ID: 30645835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the WHO-ART terminology on Snomed CT to improve grouping of related adverse drug reactions.
    Alecu I; Bousquet C; Mougin F; Jaulent MC
    Stud Health Technol Inform; 2006; 124():833-8. PubMed ID: 17108616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The medical dictionary for regulatory activities (MedDRA).
    Brown EG; Wood L; Wood S
    Drug Saf; 1999 Feb; 20(2):109-17. PubMed ID: 10082069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application analysis of adverse drug reaction terminology WHOART and MedDRA].
    Liu J; Xie YM; Gai GZ; Liao X
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4728-33. PubMed ID: 27245013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription-event monitoring in Japan (J-PEM).
    Kubota K
    Drug Saf; 2002; 25(6):441-4. PubMed ID: 12071781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
    Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
    Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience using MedDRA for global events coding in HIV clinical trials.
    Tonéatti C; Saïdi Y; Meiffrédy V; Tangre P; Harel M; Eliette V; Dormont J; Pierre Aboulker J
    Contemp Clin Trials; 2006 Feb; 27(1):13-22. PubMed ID: 16288902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic ineffectiveness: heads or tails?
    Figueras A; Pedrós C; Valsecia M; Laporte JR
    Drug Saf; 2002; 25(7):485-7. PubMed ID: 12093306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OntoADR a semantic resource describing adverse drug reactions to support searching, coding, and information retrieval.
    Souvignet J; Declerck G; Asfari H; Jaulent MC; Bousquet C
    J Biomed Inform; 2016 Oct; 63():100-107. PubMed ID: 27369567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach.
    Bousquet C; Henegar C; Louët AL; Degoulet P; Jaulent MC
    Int J Med Inform; 2005 Aug; 74(7-8):563-71. PubMed ID: 15955732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using SNOMED CT in combination with MedDRA for reporting signal detection and adverse drug reactions reporting.
    Bodenreider O
    AMIA Annu Symp Proc; 2009 Nov; 2009():45-9. PubMed ID: 20351820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance.
    Lee S; Han J; Park RW; Kim GJ; Rim JH; Cho J; Lee KH; Lee J; Kim S; Kim JH
    Drug Saf; 2019 May; 42(5):657-670. PubMed ID: 30649749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.